WHO recommends that Therapeutic Efficacy Studies (TES) for 1st and 2nd line antimalarial
medicines should be routinely carried out and data made available for decision-making due to
the threat of emergence and spread of artemisinin resistance in malaria-endemic countries,
especially in Africa. In line with this WHO recommendation, Kenya Ministry of Health (MOH) is
conducting the TES to determine the efficacy of artemether lumefantrine (AL), and
dihydroartemisinin-piperaquine (DHP), the first and second line treatment of uncomplicated
malaria in Kenya. The objective of this study is to inform the decisions or actions made by a
public health authority (Kenya Ministry of Health) to inform decision on revision of the
antimalarial guidelines and policy in Kenya. Jhpiego's Impact Malaria project in Kenya, with
funding and technical oversight from US President's Malaria Initiative (PMI) through USAID
and CDC, will support the Kenya MOH in its effort to evaluate the efficacy of AL and DHP in
the treatment of children with uncomplicated malaria. The study is being conducted by Kenya
MOH, with technical support and funding by PMI-USAID through Jhpiego in Kenya.
Phase:
Phase 4
Details
Lead Sponsor:
Jhpiego
Collaborators:
Centers for Disease Control and Prevention Kenya Ministry of Health United States Agency for International Development (USAID)
Treatments:
Artemether Artemether, Lumefantrine Drug Combination Artenimol Dihydroartemisinin Lumefantrine Piperaquine